Recent assessments on the neurobiology of major depression: A critical review;Recenti acquisizioni sulla neurobiologia della depressione maggiore: Una revisione critica

Rivista di Psichiatria

Volumn 43, Issue 4, 2008, Pages 185-207

  Altamura, Alfredo Carlo ^a   Dell'Osso, Bernardo ^a   Serati, Marta ^a   Ciabatti, Mariateresa ^a   Buoli, Massimiliano ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Immune system; Major depression; Neurobiology; Neuroendocrine system; Neurotransmitters abnormalities

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLCHOLINE; ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; DEXAMETHASONE; DOPAMINE; FLUOXETINE; GALANIN; GLUTAMIC ACID; IMIPRAMINE; KETAMINE; METABOTROPIC RECEPTOR ANTAGONIST; METHYLDOPA; MONOAMINE; NEUROKININ 1 RECEPTOR ANTAGONIST; NORADRENALIN; PHENELZINE; PINDOLOL; PROPRANOLOL; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SUBSTANCE P; SUBSTANCE P ANTAGONIST; TRAZODONE; VASOPRESSIN RECEPTOR ANTAGONIST;

COGNITION; HUMAN; IMMUNE STATUS; MAJOR DEPRESSION; NEUROBIOLOGY; NEUROENDOCRINE SYSTEM; NEUROTRANSMISSION; NONHUMAN; PATHOPHYSIOLOGY; REMISSION; REVIEW;

EID: 48249116462     PISSN: 00356484     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (211)

1. Nierenberg AA, De Cecco LM: Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. The Journal of Clinical Psychiatry, 2001, 62, 5-9.
2. Thase ME: Effectiveness of antidepressants: comparative remission rates. The Journal of Clinical Psychiatry, 2003, 64, 3-7.
3. Robinson DS: The role of dopamine and norepinephrine in depression. Primary Psychiatry, 2007, 14, 21-23.
4. Hood SD, Bell CJ, Nutt DJ: Acute tryptophan depletion. Part I: rationale and methodology. Australian and New Zeland Journal of Psychiatry, 2005, 39, 558-564.
5. Fernstrom JD: Diet-induced changes in plasma amino acid pattern: effects on the brain uptake of large neutral amino acids, and on brain serotonin synthesis. Journal of Neural Transmission, Supplementum, 1979, 55-67.
6. Shopsin B, Gershon S, Goldstein M, Friedman E, Wilk S: Use of synthesis inhibitors in defining a role for biogenic amines during imipramine treatment in depressed patients. Psychopharmacology Communications, 1975, 1, 239-249.
7. Shopsin B, Friedman E, Gershon S: Parachlorophenylalanine reversal of tranylcypromine effects in depressed patients. Archives of General Psychiatry, 1976, 33, 811-819.
8. Anderson IM, Parry-Billings M, Newsholme EA, Fairburn CG, Cowen PJ: Dieting reduces plasma tryptophan and alters brain 5-HT function in women. Psychological Medicine, 1990, 20, 785-791.
9. Reilly JG, McTavish SFB, Young AH: Rapid depletion of plasma tryptophan: a review of studies and experimental methodology. Journal of Psychopharmacology, 1997, 11, 381-392.
10. Spillmann MK, Van der Does AJ, Rankin MA, Vuolo RD, Alpert JE, Nierenberg AA, et al.: Tryptophan depletion in SSRI-recovered depressed outpatients. Psychopharmacology, 2001, 155, 123-127.
11. Van der Does AJ: The mood-lowering effect of tryptophan depletion: possible explanation for discrepant findings. Archives of General Psychiatry, 2001, 58, 200-202.
12. Ellenbogen MA, Young SN, Dean P, Palmour RM, Benkelfat C: Mood response to acute tryptophan depletion in healthy volunteers: sex differences and temporal stability. Neuropsychopharmacology, 1996, 15, 465-474.
13. Smith KA, Clifford EM, Hockney RA, Clark DM, Cowen PJ: Effect of tryptophan depletion on mood in male and female volunteers: a pilot study. Human Psychopharmacology, 1997, 12, 111-117.
14. Bell CJ, Hood SD, Nutt DJ: Acute tryptophan depletion. Part II: clinical effects and implications. Australian and New Zeland Journal of Psychiatry, 2005, 39, 565-574.
15. Delgado PL, Price LH, Miller HL, Salomon RM, Aghajanian GK, Heninger GR, et al.: Serotonin and the neurobiology of depression. Effects of tryptophan depletion in drug-free depressed patients. Archives of General Psychiatry, 1994, 51, 865-874.
16. Neumeister A, Praschak-Rieder N, Hesselmann B, Vitouch O, Rauh M, Barocka A, et al.: Rapid tryptophan depletion in drug-free depressed patients with seasonal affective disorder. American Journal of Psychiatry, 1997, 154, 1153-1155.
17. Price LH, Malison RT, McDougle CJ, McCance-Katz EF, Owen KR, Heninger GR: Neurobiology of tryptophan depletion in depression: effects of m-chlorophenylpiperazine (mCPP). Neuropsychopharmacology, 1997, 17, 342-350.
18. Price LH, Malison RT, McDougle CJ, Pelton GH, Heninger GR: The neurobiology of tryptophan depletion in depression: effects of intravenous tryptophan infusion. Biological Psychiatry, 1998, 43, 339-347.
19. Bel N, Artigas F: Reduction of serotonergic function in rat brain by tryptophan depletion: effects in control and fluvoxamine-treated rats. Journal of Neurochemistry, 1996, 67, 669-676.
20. Aberg-Wistedt A, Hasselmark L, Stain-Malmgren R, Apéria B, Kjellman BF, Mathé AA: Serotonergic 'vulnerability' in affective disorder: a study of the tryptophan depletion test and relationships between peripheral and central serotonin indexes in citalopram-responders. Acta Psychiatrica Scandinavica, 1998, 97, 374-380.
21. Delgado PL, Miller HL, Salomon RM, Licinio J, Krystal JH, Moreno FA, et al.: Tryptophan depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action. Biological Psychiatry, 1999, 46, 212-220.
22. Delgado PL, Charney DS, Price LH, Aghajanian GK, Landis H, Heninger GR: Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Archives of General Psychiatry, 1990, 47, 411-418.
23. Smith KA, Morris JS, Friston KJ, Cowen PJ, Dolan RJ: Brain mechanisms associated with depressive relapse and associated cognitive impairment following acute tryptophan depletion. British Journal of Psychiatry, 1999, 174, 525-529.
24. Moore P, Gillin C, Bhatti T, DeModena A, Seifritz E, Clark C, et al.: Rapid tryptophan depletion, sleep electroencephalogram, and mood in men with remitted depression on serotonin reuptake inhibitors. Archives of General Psychiatry, 1998, 55, 534-539.
25. Moreno FA, Heninger GR, McGahuey CA, Delgado PL: Tryptophan depletion and risk of depression relapse: a prospective study of tryptophan depletion as a potential predictor of depressive episodes. Biological Psychiatry, 2000, 48, 327-329.
26. Leyton M, Young SN, Blier P, Ellenbogen MA, Palmour RM, Ghadirian AM, et al.: The effect of tryptophan depletion on mood in medication-free, former patients with major affective disorder. Neuropsychopharmacology, 1997, 16, 294-297.
27. Delgado PL, Price LH, Miller HL, Salomon RM, Licinio J, Krystal JH, et al.: Rapid serotonin depletion as a provocative challenge test for patients with major depression: relevance to antidepressant action and the neurobiology of depression. Psychopharmacology Bulletin, 1991, 27, 321-330.
28. Miller HL, Delgado PL, Salomon RM, Berman R, Krystal JH, Heninger GR, et al.: Clinical and biochemical effects of catecholamine depletion on antidepressant-induced remission of depression. Archives of General Psychiatry, 1996, 53, 117-128.
29. Neumeister A, Praschak-Rieder N, Hesselmann B, Vitouch O, Rauh M, Barocka A, et al.: Effects of tryptophan depletion in fully remitted patients with seasonal affective disorder during summer. Psychological Medicine, 1998, 28, 257-264.
30. Smith KA, Fairburn CG, Cowen PJ: Relapse of depression after rapid depletion of tryptophan. The Lancet, 1997, 349, 915-919.
31. Leyton M, Young SN, Pihl RO, Etezadi S, Lauze C, Blier P, et al.: Effects on mood of acute phenylalanine/tyrosine depletion in healthy women. Neuropsychopharmacology, 2000, 22, 52-63.
32. Moreno FA, Gelenberg AJ, Heninger GR, Potter RL, McKnight KM, Allen J, et al.: Tryptophan depletion and depressive vulnerability. Biological Psychiatry, 1999, 46, 498-505.
33. Leyton M, Young SN, Blier P, Ellenbogen MA, Palmour RM, Ghadirian AM, et al.: The effect of tryptophan depletion on mood in medication-free, former patients with major affective disorder. Neuropsychopharmacology, 1997, 16, 294-297.
34. Lam RW, Bowering TA, Tam EM, Grewal A, Yatham LN, Shiah IS, et al.: Effects of rapid tryptophan depletion in patients with seasonal affective disorder in natural summer remission. Psychological Medicine, 2000, 30, 79-87.
35. Neumeister A, Habeler A, Praschak-Rieder N, Willeit M, Kasper S: Tryptophan depletion: a predictor of future depressive episodes in seasonal affective disorder? International Clinical Psychopharmacology, 1999, 14, 313-315.
36. Kapur S, Mann JJ: Role of the dopaminergic system in depression. Biological Psychiatry, 1992, 32, 1-17.
37. Randrup A, Munkvad I, Fog R, Molauder L, Kjellberg B: Mania, depression, and brain dopamine. In: Essman W, Valzelli L (eds). Current Developments in Psychopharmacology. Spectrum Publications, New York, 1975.
38. Malhi GS, Berk M: Does dopamine dysfunction drive depression? Acta Psychiatrica Scandinavica, 2007, 115, 116-124.
39. Pier MPBI, Hulstijn W, Sabbe BGC: Differential patterns of psychomotor functioning in unmedicated melancholic and nonmelancholic depressed patients. Journal of Psychiatric Research, 2004, 38, 425-435.
40. Rogers MA, Bradshaw JL, Phillips JG, Chiu E: Reliance on external cues during serial sequential movement in major depression. Journal of Neurology, Neurosurgery & Psychiatry, 2000, 69, 237-239.
41. Rogers MA, Bradshaw JL, Phillips JG, Chiu E, Vaddadi K, Presnel I, et al.: Parkinsonian motor characteristics in unipolar major depression. Journal of Clinical and Experimental Neuropsychology, 2000, 22, 232-244.
42. Caligiuri MP, Ellwanger J: Motor and cognitive aspects of motor retardation in depression. Journal of Affective Disorders, 2000, 57, 83-93.
43. Sachdev P, Aniss AM: Slowness of movement in melancholic depression. Biological Psychiatry, 1994, 35, 253-262.
44. Leentjens AF, Van den Akker M, Metsemakers JF, Lousberg B, Verhey FR: Higher incidence of depression preceding the onset of Parkinson's disease: a register study. Movement Disorders, 2003, 18, 414-418.
45. Nilsson FM, Kessing LV, Bolwig TG: Increased risk of developing Parkinson's disease for patients with major affective disorder: a register study. Acta Psychiatrica Scandinavica, 2001, 104, 380-386.
46. Nilsson FM, Kessing LV, Sorensen TM, Anderesen PK, Bolwig TG: Major depressive disorder in Parkinson's disease: a register-based study. Acta Psychiatrica Scandinavica, 2002, 106, 202-211.
47. Klimek V, Schenck JE, Han H, Stockmeier CA, Ordway GA: Dopaminergic abnormalities in amygdaloid nuclei in major depression: a postmortem study. Biological Psychiatry, 2002, 52, 740-748.
48. Lyness SA, Eaton EM, Schneider LS: Cognitive performance in older and middle-aged depressed outpatients and controls. Journal of Gerontology, 1994, 49, 129-136.
49. Goldberg JF, Burdick KE, Endick CJ: Preliminary randomized, double-blind, placebo controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. The American Journal of Psychiatry, 2004, 161, 564-566.
50. Zarate CA Jr, Payne JL, Singh J, Quiroz JA, Luckenbaugh DA, Denicoff KD, et al.: Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biological Psychiatry, 2004, 56, 54-60.
51. Ge S, Dani JA: Nicotinic acetylcholine receptors at glutamate synapses facilitate long-term depression or potentiation. The Journal of Neuroscience, 2005, 25, 6084-6091.
52. Risch SC, Kalin NH, Janowsky DS: Cholinergic challenges in affective illness: behavioral and neuroendocrine correlates. Journal of Clinical Psychopharmacology, 1981, 1, 186-192.
53. Leboyer M, Plaisant O: Cholinergic hypothesis of depression. L'Encéphale, 1985, 11, 229-234.
54. Bachman ES, Berger-Sweeney J, Coyle JT, Hohmann CF: Developmental regulation of adult cortical morphology and behaviour: an animal model for mental retardation. International Journal of Developmental Neuroscience, 1994, 12, 239-253.
55. Hohmann CF, Berger-Sweenney J: Cholinergic regulation of cortical development. New twists on an old story. Perspectives of Developmental Neurobiology, 1998, 5, 401-425.
56. Freo U, Pizzolato G, Dam M, Ori C, Battistin L: A short review of cognitive and functional neuroimaging studies of cholinergic drugs: implications for therapeutic potentials. Journal of Neural Transmission, 2002, 109, 857-870.
57. Furey ML, Pietrini P, Alexander GE, Schapiro MB, Horwitz B: Cholinergic enhancement improves performance on working memory by modulating the functional activity in distinct brain regions: a positron emission tomography regional cerebral blood flow study in healthy humans. Brain Research Bullettin, 2000, 51, 213-218.
58. Furey ML, Drevets WC: Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Archives of General Psychiatry, 2006, 63, 1121-1129.
59. Kornum BR, Weikop P, Moller A, Ronn LC, Knudsen GM, Aznar S: Serotonin depletion results in a decrease of the neuronal activation caused by rivastigmine in the rat hippocampus. Brain Research, 2006, 1073-1074, 262-268. Epub 2006 Jan 19.
60. Riemann D, Hohagen F, Fritsch-Montero R, Krieger S, Gann H, Dressing H, et al.: Cholinergic and noradrenergic neurotransmission: impact on REM sleep regulation in healthy subjects and depressed patients. Acta Psychiatrica Belgica, 1992, 92, 151-171.
61. Machowski R, Ansseau M, Charles G, Schittecatte M, Wilmotte J: Latencies of REM sleep and awakening in major depression: possible indicators of cholinergic activity. Neurophysiologie Clinique, 1989, 19, 385-391.
62. Overstreet DH, Russell RW, Crocker AD, Gillin JC, Janowsky DS: Genetic and pharmacological models of cholinergic supersensitivity and affective disorders. Experientia, 1988, 44, 465-472.
63. Fritze J: The adrenergic-cholinergic imbalance hypothesis of depression: a review and a perspective. Reviews in the Neurosciences, 1993, 4, 63-93.
64. Bertrand D: The possible contribution of neuronal nicotinic acetylcholine receptors in depression. Dialogues in Clinical Neurosciences, 2005, 7, 207-216.
65. Wang JC, Hinrichs AL, Stock H, Budde J, Allen R, Bertelsen S, et al.: Evidence of common and specific genetic effects: association of the muscarinic acetylcholine receptor M2 (CHRM2) gene with alcohol dependence and major depressive syndrome. Human Molecular Genetics, 2004, 13, 1903-1911.
66. Javitt DC, Zukin SR: The role of excitatory amino acids in neuropsychiatric illness. The Journal of Neuropsychiatry and Clinical Neurosciences, 1990, 2, 44-52.
67. Kendell SF, Krystal JH, Sanacora G: GABA and glutamate systems as therapeutic targets in depression and mood disorders. Expert Opinion on Therapeutic Targets, 2005, 9, 153-168.
68. Altamura CA, Mauri MC, Ferrara A, Moro AR, D'Andrea G, Zamberlan F: Plasma and platelet excitatory amino acids in psychiatric disorders. The American Journal of Psychiatry, 1993, 150, 1731-1733.
69. Altamura C, Maes M, Dai J, Meltzer HY: Plasma concentrations of excitatory amino acids, serine, glycine, taurine and histidine in major depression. European Neuropsychopharmacology, 1995, 5, 71-75.
70. Maes M, Verkerk R, Vandoolaeghe E, Lin A, Scharpé S: Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: modulation by treatment with antidepressants and prediction of clinical responsivity. Acta Psychiatrica Scandinavica, 1998, 97, 302-308.
71. Rosenberg DR, Macmaster FP, Mirza Y, Smith JM, Easter PC, Banerjee SP, et al.: Reduced anterior cingulate glutamate in pediatric major depression: a magnetic resonance spectroscopy study. Biological Psychiatry, 2005, 58, 700-704.
72. Frye MA, Tsai GE, Huggins T, Coyle JT, Post RM: Low cerebrospinal fluid glutamate and glycine in refractory affective disorder. Biological Psychiatry, 2007, 61, 162-166.
73. Hashimoto K, Sawa A, Iyo M: Increased levels of glutamate in brains from patients with mood disorders. Biological Psychiatry, 2007, 62, 1310-1316.
74. Muller N, Schwarz MJ: The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Molecular Psychiatry, 2007, 12, 988-1000.
75. Berk M, Plein H, Ferreira D: Platelet glutamate receptor supersensitivity in major depressive disorder. Clinical Neuropharmacology, 2001, 24, 129-132.
76. Palucha A, Pilc A: The involvement of glutamate in the pathophysiology of depression. Drugs News & Perspectives, 2005, 18, 262-268.
77. Bleakman D, Alt A, Witkin JM: AMPA receptors in the therapeutic management of depression. CNS & Neurological Disorders Drug Targets, 2007, 6, 117-126.
78. Paul IA, Skolnick P: Glutamate and depression: clinical and preclinical studies. Annals of the New York Academy of Sciences, 2003, 1003, 250-272.
79. Michael-Titus AT, Bains S, Jeetle J, Whelpton R: Imipramine and phenelzine decrease glutamate overflow in the prefrontal cortex: a possible mechanism of neuroprotection in major depression? Neuroscience, 2000, 100, 681-684.
80. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al.: Antidepressant effects of ketamine in depressed patients. Biological Psychiatry, 2000, 47, 351-354.
81. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al.: A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry, 2006, 63, 856-864.
82. Zarate CA Jr, Payne JL, Quiroz J, Sporn J, Denicoff KK, Luckenbaugh D, et al.: An open-label trial of riluzole in patients with treatment-resistant major depression. The American Journal of Psychiatry, 2004, 161, 171-174.
83. Palucha A: Are compounds acting at metabotropic glutamate receptors the answer to treating depression? Expert Opinion on Investigational Drugs, 2006, 15, 1545-1553.
84. Mateo Z, Porter JT: Group II metabotropic glutamate receptors inhibit glutamate release at thalamocortical synapses in the developing somatosensory cortex. Neuroscience, 2007, 146, 1062-1072.
85. Witkin JM, Marek GJ, Johnson BG, Schoepp DD: Metabotropic glutamate receptors in the control of mood disorders. CNS & Neurological Disorders Drug Targets, 2007, 6, 87-100.
86. Mitsukawa K, Mombereau C, Lotscher E, Uzunov DP, van der Putten H, Flor PJ, et al.: Metabotropic glutamate receptor subtype 7 ablation causes dysregulation of the HPA axis and increases hippocampal BDNF protein levels: implications for stress-related psychiatric disorders. Neuropsychopharmacology, 2006, 31, 1112-1122.
87. Norman TR, Burrows GD: Emerging treatments for major depression. Expert Review of Neurotherapeutics, 2007, 7, 203-213.
88. Adell A: Antidepressant properties of substance P antagonists: relationship to monoaminergic mechanisms? Current Drug Targets. CNS and Neurological Disorders, 2004, 3, 113-121.
89. Duffy RA: Potential therapeutic targets for neurokinin-1 receptor antagonists. Expert Opinion on Emerging Drugs, 2004, 9, 9-21.
90. Alvaro G, Di Fabio R: Neurokinin 1 receptor antagonists: current prospects. Current Opinion in Drug Discovery & Development, 2007, 10, 613-621.
91. Herpfer I, Lieb K: Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential. CNS Drugs, 2005, 19, 275-293.
92. Ebner K, Singewald N: Stress-induced release of substance P in the locus coeruleus modulates cortical noradrenaline release. Naunyn Schmiedeberg's Archives of Pharmacology, 2007, 376, 73-82.
93. Boselli C, Barbone MS, Lucchelli A: Older versus newer antidepressants: substance P or calcium antagonism? Canadian Journal of Physiology and Pharmacology, 2007, 85, 1004-1011.
94. Chenu F, Guiard BP, Bourin M, Gardier AM: Antidepressant-like activity of selective serotonin reuptake inhibitors combined with a NK1 receptor antagonist in the mouse forced swimming test. Behavioural Brain Reserach, 2006, 172, 256-263.
95. Bondy B, Baghai TC, Minov C, Schüle C, Schwarz MJ, Zwanzger P, et al.: Substance P serum levels are increased in major depression: preliminary results. Biological Psychiatry, 2003, 53, 538-542.
96. Lieb K, Walden J, Grunze H, Fiebich BL, Berger M, Normann C: Serum levels of substance P and response to antidepressant pharmacotherapy. Pharmacopsychiatry, 2004, 37, 238-239.
97. Carpenter LL, Bayat L, Moreno F, Kling MA, Price LH, Tyrka AR, et al.: Decreased cerebrospinal fluid concentrations of substance P in treatment-resistant depression and lack of alteration after acute adjunct vagus nerve stimulation therapy. Psychiatry Research, 2008, 157, 123-129.
98. Kramer MS, Winokur A, Kelsey J, Preskorn SH, Rothschild AJ, Snavely D, et al.: Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology, 2004, 29, 385-392.
99. Haddjeri N, Blier P: Sustained blockade of neurokinin-1 receptors enhances serotonin neurotransmission. Biological Psychiatry, 2001, 50, 191-199.
100. Rupniak NM: Elucidating the antidepressant actions of substance P (NK1 receptor) antagonists. Current Opinion in Investigational Drugs, 2002, 3, 257-261.
101. Keller M, Montgomery S, Ball W, Morrison M, Snavely D, Liu G, et al.: Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biological Psychiatry, 2006, 59, 216-223.
102. Vrontakis ME: Galanin: a biologically active peptide. Current Drug Targets. CNS and Neurological Disorders, 2002, 1, 531-541.
103. Weiss JM, Bonsall RW, Demetrikopoulos MK, Emery MS, West CH: Galanin: a significant role in depression? Annals of the New York Academy of Sciences, 1998, 863, 364-382.
104. Ogren SO, Kuteeva E, Hökfelt T, Kehr J: Galanin receptor antagonists: a potential novel pharmacological treatment for mood disorders. CNS Drugs, 2006, 20, 633-654.
105. Ogren SO, Razani H, Elvander-Tottie E, Kehr J: The neuropeptide galanin as an in vivo modulator of brain 5-HT1A receptors: possible relevance for affective disorders. Physiology and Behavior, 2007, 92, 172-179.
106. Lu X, Barr AM, Kinney JW, Sanna P, Conti B, Behrens MM, et al.: A role for galanin in antidepressant actions with a focus on the dorsal raphe nucleus. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 874-879.
107. Stahl S: Psicofarmacologia essenziale. Centro Scientifico Editore, Torino, 2002.
108. Petty F, Kramer GL, Dunnam D, Rush AJ: Plasma GABA in mood disorders. Psychopharmacology Bullettin, 1990, 26, 157-161.
109. Petty F, Kramer GL, Fulton M, Davis L, Rush AJ: Stability of plasma GABA at four-year follow-up in patients with primary unipolar depression. Biological Psychiatry, 1995, 37, 806-810.
110. Hasler G, Neumeister A, van der Veen JW.Tumonis T, Bain EE, Shen J, et al.: Normal prefrontal gamma-aminobutyric acid levels in remitted depressed subjects determined by proton magnetic resonance spectroscopy. Biological Psychiatry, 2005, 58, 969-973.
111. Hasler G, van der Veen JW, Tumonis T, Meyers N, Shen J, Drevets WC: Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Archives of General Psychiatry, 2007, 64, 193-200.
112. Sanacora G, Mason GF, Rothman DL, Kristal JH: Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. The American Journal of Psychiatry, 2002, 159, 663-665.
113. Palmio J, Huuhka M, Saransaari P, Oja SS, Peltola J, Leinonen E, et al.: Changes in plasma amino acids after electroconvulsive therapy of depressed patients. Psychiatry Research, 2005, 137, 183-190.
114. Sanacora G, Fenton RL, Fasula MK, Rothman DL, Levin Y, Krystal JH, et al.: Cortical gamma-aminobutyric acid concentrations in depressed patients receiving cognitive behavioral therapy. Biological Psychiatry, 2006, 59, 284-286.
115. Bielau H, Steiner J, Mawrin C, Trübner K, Brisch R, Meyer-Lotz G, et al.: Dysregulation of GABAergic neurotransmission in mood disorders: a postmortem study. Annals of the New York Academy of Sciences, 2007, 1096, 157-169.
116. Rajkowska G, Miguel-Hidalgo JJ: Gliogenesis and glial pathology in depression. CNS & Neurological Disorders Drug Targets, 2007, 6, 219-233.
117. Bahgwagar Z, Wylezinska M, Jezzard P, Evans J, Boorman E, Matthews MP, et al.: Low GABA concentrations in occipital cortex and anterior cingulate cortex in medication-free, recovered depressed patients. The International Journal of Neuropsychopharmacology, 2008, 11, 255-260.
118. Choudary PV, Molnar M, Evans SJ, Tomita H, Li JZ, Vawter MP, et al.: Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 15653-15658.
119. Sequeira A, Klempan T, Canetti L, Ffrench-Mullen J, Benkelfat C, Rouleau GA, et al.: Patterns of gene expression in the limbic system of suicides with and without major depression. Molecular Psychiatry, 2007, 12, 640-655.
120. Nolte J: The human brain. Ed. St. Louis, Mosby, 2002.
121. Waxman SG: Clinical neuroanatomy. Lange Medical Books/McGraw Hill Ed, New York, 2003.
122. Nibuya M, Nestler EJ, Duman RS: Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. The Journal of Neuroscience, 1996, 16, 2365-2372.
123. Stahl SM: Blue genes and monoamine hypothesis of depression. Journal of Clinical Psychiatry, 2000, 61, 77-78.
124. Nakagawa S, Kim J, Lee R Malberg JE, Chen J, Steffen C, et al.: Regulation of neurogenesis in adult mouse hippocampus by cAMP and the cAMP response element-binding protein. The Journal of Neuroscience, 2002, 22, 3673-3682.
125. Fujioka T, Fujioka A, Duman RS: Activation of cAMP signalling facilitates the morphological maturation of newborn neurons in adult hippocampus. The Journal of Neuroscience, 2004, 24, 319-328.
126. Coyle JT, Duman RS: Finding the intracellular signaling pathways affected by mood disorders treatments. Neuron, 2003, 38, 157-160.
127. Garcia-Sevilla JA, Escriba PV, Ozaita, A, La Harpe R, Walzer C, Eytan A, et al.: Up-regulation of immunolabeled alpha2A-adrenoceptors, Gi coupling proteins, and regulatory receptor kinases in the prefrontal cortex of depressed suicides. Journal of Neurochemistry, 1999, 72, 282-291.
128. Rosner W, Hryb DJ, Khan MS, Nakhla AM, Romas NM: Androgens, estrogens and second messengers. Steroids, 1998, 63, 278-281.
129. Licinio J, Wong ML: Pathways and mechanisms for cytokine signaling of the central nervous system. The Journal of Clinical Investigation, 1997, 100, 2941-2947.
130. Kielcolt-Glaser JK, Glaser R: Depression and immune function: central pathways to morbidity and mortality. Journal of Psychosomatic Research, 2002, 53, 873-876.
131. Maes M, Vandoolaeghe E, Ranjan R, Bosmans E, Bergmans R, Desnyder R: Increased serum interleukin-1-receptor-antagonist concentrations in major depression. Journal of Affective Disorders, 1995, 36, 29-36.
132. Maes M: Major depression and activation of the inflammatory response system. Advances in Experimental Medicine and Biology, 1999, 461, 25-46.
133. Chapman LF, Ramos AO, Goodell H, Wolff HG: Evidence for kinin formation resulting from neural activity evoked by noxious stimulation. Annals of the New York Academy of Sciences, 1963, 104, 258-274.
134. Wichers M, Maes M: The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. The International Journal of Neuropsychopharmacology, 2002, 5, 375-388.
135. Mossner R, Daniel S, Schmitt A, Albert D, Lesch KP: Modulation of serotonin transporter function by interleukin-4. Life Sciences, 2001, 68, 873-880.
136. Wichers MC, Koek GH, Robaeys G, Verkerk R, Scharpé S, Maes M: IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Molecular Psychiatry, 2005, 10, 538-544.
137. Leonard BE: The immune system, depression and the action of antidepressants. Progress in Neuropsychopharmacology & Biological Psychiatry, 2001, 25, 767-780.
138. Raison C, Capuron L, Miller AH: Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends in immunology, 2006, 27, 24-31.
139. Schiepers OJ, Wichers MC, Maes M: Cytokines and major depression. Progress in Neuropsychopharmacology & Biological Psychiatry, 2005, 29, 201-217.
140. Altamura A, Cattaneo E, Mundo E, Pozzoli S, Trabattoni D, Arosio B, et al.: Polymorphisms of the MCP-1 and IL-10 genes and mood disorders: an association study. Schizophrenia Research, 2008, 98, 95.
141. Rothermundt M, Arolt V, Peters M, Gutbrodt H, Fenker J, Kersting A, et al.: Inflammatory markers in major depression and melancholia. Journal of Affective Disorders, 2001, 63, 93-102.
142. Robertson G: In: Seiden D, Giebisch C (eds). The kidney: pathophysiology and pathophysiology. Raven Press, New York, 1992.
143. Arborelius L, Owens MJ, Plotski PM, Nemeroff CB: The role of corticotrophin-releasing factor in depression and anxiety disorder. The Journal of Endocrinology, 1999, 160, 1-12.
144. Bao AM, Meynen G, Swaab DF: The stress system in depression and neurodegeneration: focus on the human hypothalamus. Brain Research Reviews, 2007, Epub ahead of print.
145. Dinan TG: Glucocorticoids and the genesis of depressive illness. British Journal of Psychiatry, 1994, 164, 365-371.
146. Chalouff F: Physiopharmacological interactions between stress hormones and central serotoninergic system. Brain Research Reviews, 1993, 18, 1-32.
147. Sapolsky R, Rivier C, Yamamoto G, Plotsky P, Vale W: Interleukin-1 stimulates the secretion of hypothalamic corticotropin-releasing factor. Science, 1987, 238, 522-524.
148. Miller AH, Pariante CM, Pearce BD: Effects of cytokines on glucocorticoid receptor expression and function. Glucocorticoid resistance and relevance to depression. Advances in Experimental Medicine and Biology, 1999, 461, 107-116.
149. Thomson F, Craighead M: Innovative Approaches for the Treatment of Depression: targeting the HPA Axis. Neurochemical Research, 2008, 33, 691-707.
150. Rubin RT, Poland RE, Lesser IM, Martin DJ: Neuroendocrine aspects of primary endogenous depression. V. Serum prolactin measures in patients and matched control subject. Biological Psychiatry, 1989, 25, 4-21.
151. Sachar EJ, Baron M: The biology of affective disorders. Annual Review of Neuroscience, 1979, 2, 505-517.
152. Mason BL, Pariante CM: The effects of antidepressants on the hypothalamic-pituitary-adrenal axis. Drug News & Perspectives, 2006, 19, 603-608.
153. Araya AV, Rojas P, Fritsch R, Rojas R, Herrera L, Rojas G, et al.: Early response to venlafaxine antidepressant correlates with lower ACTH levels prior to pharmacological treatment. Endocrine, 2006, 30, 289-298.
154. Scott LV, Dinan TG: Vasopressin and the regulation of hypothalamic-pituitary-adrenal axis function: implications for the pathophysiology of depression. Life Sciences, 1998, 62, 1985-1998.
155. Meynen G, Unmehopa UA, van Heerikhuize JJ, Hofman MA, Swaab DF, Hoogendijk WJ: Increased arginine vasopressin mRNA expression in the human hypothalamus in depression: a preliminary report. Biological Psychiatry, 2006, 60, 892-895.
156. Kaplan HI, Sadock BJ: Psichiatria. Centro Scientifico Editore, Torino, 2001.
157. Fountoulakis KN, Kantartzis S, Siamouli M, Panagiotidis P, Kaprinis S, Iacovides A, et al.: Peripheral thyroid dysfunction in depression. The World Journal of Biological Psychiatry, 2006, 7, 131-137.
158. Duval F, Mokrani MC, Bailey P, Correa H, Diep TS, Crocq MA, et al.: Thyroid axis activity and serotonin function in major depressive episode. Psychoneuroendocrinology, 1999, 24, 695-712.
159. Gordon JT, Kaminski DM, Rozanov CB, Dratman MB: Evidence that 3,3′,5-triiodothyronine is concentrated in and delivered from the locus coeruleus to its noradrenergic targets via anterograde axonal tran sport. Neuroscience, 1999, 93, 943-954.
160. Abraham G, Milev R, Stuart Lawson J: T3 augmentation of SSRI resistant depression. Journal of Affective Disorders, 2006, 91, 211-215.
161. Cooper-Kazaz R, Apter JT, Cohen R, Karagichev L, Muham-med-Moussa S, Grupper D, et al.: Combined treatment with sertraline and liothyronine in major depression: a randomized, double-blind, placebo-controlled trial. Archives of General Psychiatry, 2007, 64, 679-688.
162. Brouwer JP, Appelhof BC, Hoogendijk WJ, Huyser J, Endert E, Zuketto C, et al.: Thyroid and adrenal axis in major depression: a controlled study in outpatients. European Journal of Endocrinology, 2005, 152, 185-191.
163. Abulseoud O, Sane N, Cozzolino A, Kiriakos L, Mehra V, Gitlin M, et al.: Free T4 index and clinical outcome in patients with depression. Journal of Affective Disorders, 2007, 100, 271-277.
164. Gasperini M, Lucca A, Manfredonia MG, Perez J, Zanardi R: Basi biologiche, inquadramento nosografico e trattamento farmacologico dei disturbi dell'umore. Trattato di Neuropsicofarmacologia, UTET, 1998.
165. Stotland NL, Stotland NE: Depression in women. Obstetrical & Gynecological Survey, 1999, 54, 519-525.
166. Bloch M, Schmidt PJ, Danaceau M, Murphy J, Nieman L, Rubinow DR: Effects of gonadal steroids in women with a history of postpartum depression. The American Journal of Psychiatry, 2000, 157, 924-930.
167. Fink G, Sumner BE, Rosie R, Grace O, Quinn JP: Estrogen control of central neurotransmission: effect on mood, mental state, and memory. Cellular and Molecular Neurobiology, 1996, 16, 325-344.
168. Halbreich U, Kahn LS: Role of estrogen in the aetiology and treatment of mood disorders. CNS Drugs, 2001, 15, 797-817.
169. Ishii H, Tsurugizawa T, Ogiue-Ikeda M, Asashima M, Mukai H, Murakami G, et al.: Local production of sex hormones and their modulation of hippocampal synaptic plasticity. The Neuroscientist, 2007, 13, 323-334.
170. Schmidt PJ, Daly RC, Bloch M, Smith MJ, Danaceau MA, St Clair LS, et al.: Dehydroepiandrosterone monotherapy in mid-life-onset major and minor depression. Archives of General Psychiatry, 2005, 62, 154-162.
171. Baulieu EE: Neurosteroids: a novel function of the brain. Psychoneuroendocrinology, 1998, 23, 963-987.
172. Majewska MD: Neurosteroids: endogenous bimodal modulator of GABA(A) receptor. Mechanism of action and physiological significant. Progress in Neurobiology, 1992, 38, 379-395.
173. Cheney DL, Uzunov D, Costa E, Guidotti A: Gas chromatographic-mass fragmentographic quantitation of 3 alpha-hydroxy-5 alpha-pregnan-20-one (allopregnanolone) and its precursors in blood and brain of adrenalectomized and castrated rats. The Journal of Neuroscience, 1995, 15, 4641-4650.
174. Smith SS: Withdrawal properties of a neuroactive steroid: implications for GABA(A) receptor gene regulation in the brain and anxiety behavior. Steroids, 2002, 67, 519-528.
175. Reddy DS, Kulkarni SK: The role of GABA-A and mitochondrial diazepam-binding inhibitor receptors on the effects of neurosteroids on food intake in mice. Psychopharmacology (Berl), 1998, 137, 391-400.
176. Prince RJ, Simmonds MA: Steroid modulation of the strychnine-sensitive glycine receptor. Neuropharmacology, 1992, 31, 201-205.
177. Irwin RP, Lin SZ, Rogawski MA, Purdy RH, Paul SM: Steroid potentiation and inhibition of N-methyl-D-aspartate receptor-mediated intracellular Ca++ responses: structure activity studies. The Journal of Pharmacology and Experimental Therapeutics, 1994, 271, 677-682.
178. Barbaccia ML, Serra M, Purdy RH, Biggio G: Stress and neuroactive steroids. International Review of Neurobiology, 2001, 46, 243-272.
179. Akwa Y, Purdy RH, Koob GF, Britton KT: The amygdala mediates the anxiolytic-like effects of the neurosteroid pregnanolone in rat. Behavioural Brain Research, 1999, 106, 119-125.
180. Jain NS, Hirani K, Chopde CT: Reversal of caffeine-induced anxiety by neurosteroid 3-alpha-hydroxy-5-alpha-pregnane-20-one in rats. Neuropharmacology, 2005, 48, 627-638.
181. Dubrovsky B, Williams D, Kraulis I: Effects of deoxycorticosterone and its ring A-reduced derivatives on the nervous system. Experimental Neurology, 1982, 78, 728-739.
182. Dubrovsky B, Filipini D, Gijsbers K, Birmingham MK: Early and late effects of steroid hormones on the nervous system. Ciba Foundation Symposium, 1990, 153, 240-257.
183. Dubrovsky B, Gijsbers K, Filipini D, Birmingham MK: Effects of adrenocortical steroids on long term potentiation in the limbic system. Basic mechanisms and behavioral consequences. Cellular and Molecular Neurobiology, 1993, 13, 399-414.
184. Spalletta G, Romeo E, Bonaviri G, Bernardi G, Caltagirone C, di Michele F: Preliminary evidence for an association between aggressive and hostile behaviors and 3alpha,5alpha-tetrahydroprogesterone plasma levels in schizophrenia. Journal of Psychiatry & Neuroscience, 2005, 30, 49-52.
185. Dubrovsky B, Tatarinov-Levin A, Harris J: Effects of the active neurosteroid THDOC on long term potentiation. Implications for depression. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 2004, 28, 1029-1034.
186. Dubrovsky B: Endocrinologia y psiquiatria. Hormonas y humores. Revista de la Universidad de Barcelona, 1995, 9, 19-38.
187. Dubrovsky B: Natural steroids counteracting some actions of putative depressogenic steroids on the central nervous system. Potential therapeutic benefits. Medical Hypotheses, 1997, 49, 51-55.
188. Wolkowitz OM, Reus VI, Keebler A, Nelson N, Friedland M, Brizendine L, et al.: Double blind treatment of major depression with deihydroepiandrosterone. The American Journal of Psychiatry, 1999, 156, 646-649.
189. Schmidt PJ, Daly RC, Bloch M, Smith MJ, Danaceau MA, St Clair LS, et al.: Dehydroepiandrosterone monotherapy in mid-life-onset major and minor depression. Archives of General Psychiatry, 2005, 62, 154-162.
190. Bloch M, Schmidt PJ, Danaceau MA, Adams LF, Rubinow DR: Dehydroepiandrosterone treatment of midlife dysthymia. Biological Psychiatry, 1999, 45, 1533-1541.
191. Altar CA: Neurotrophins and depression. Trends in Pharmacological Sciences, 1999, 20, 59-61.
192. Green T, Heinemann SF, Gusella JF: Molecular neurobiology and genetics: investigation of neural function and dysfunction. Neuron, 1998, 20, 427-444.
193. Marmigère F, Rage F, Tapia-Arancibia L: GABA-glutamate interaction in the control of BDNF expression in hypothalamic neurons. Neurochemistry International, 2003, 42, 353-358.
194. Tsai SJ: TrkB partial agonists: potential treatment strategy for major depression. Medical Hypotheses, 2007, 68, 674-676.
195. Givalois L, Naert G, Rage F, Ixart G, Arancibia S, Tapia-Arancibia L: A single brain-derived neurotrophic factor injection modifies hypothalamo- pituitary-adrenocortical axis activity in adult male rats. Molecular and Cellular Neurosciences, 2004, 27, 280-295.
196. Naert G, Maurice T, Tapia-Arancibia L, Givalois L: Neuroactive steroids modulate HPA axis activity and cerebral brain-derived neurotrophic factor (BDNF) protein levels in adult male rats. Psychoneuroendocrinology, 2007, 32, 1062-1078.
197. Sohrabji F, Miranda RC, Toran-Allerand CD: Identification of a putative estrogen response element in the gene encoding brain-derived neurotrophic factor. Proceedings of National Academy of Sciences of the United States of America, 1995, 92, 11110-11114.
198. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM: Neurobiology of depression. Neuron, 2002, 34, 13-25.
199. Duman RS, Heninger GR, Nestler EJ: A molecular and cellular theory of depression. Archives of General Psychiatry, 1997, 54, 597-606.
200. Vaidya VA, Duman RS: Depression-emerging insights from neurobiology. British Medical Bullettin, 2001, 57, 61-79.
201. Malberg JE, Eisch AJ, Nestler EJ, Duman RS: Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. The Journal of Neuroscience, 2000, 20, 9104-9110.
202. Chen B, Dowlatshahi D, MacQueen GM, Wang JF, Young LT: Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biological Psychiatry, 2001, 50, 260-265.
203. Shimizu E, Hashimoto K, Okamura N, Koike K, Komatsu N, Kumakiri C, et al.: Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biological Psychiatry, 2003, 54, 70-75.
204. Karege F, Perret G, Bondolfi G, Schwald M, Bertschy G, Aubry JM: Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Research, 2002, 109, 143-148.
205. Piccinni A, Marazziti D, Catena M, Domenici L, Del Debbio A, Bianchi C, et al.: Plasma and serum brain-derived neurotrophic factor (BDNF) in depressed patients during 1 year of antidepressant treatments. Journal of Affective Disorders, 2008, 105, 279-283.
206. Fujimura H, Altar CA, Chen R, Nakamura T, Nakahashi T, Kambayashi J, et al.: Brain-derived neurotrophic factor is sto-red in human platelets and released by agonist stimulation. Thrombosis and Haemostasis, 2002, 87, 728-734.
207. Huang TL, Lee CT, Liu YL: Serum brain-derived neurotrophic factor levels in patients with major depression: Effects of antidepressants. Journal of Psychiatric Research, 2007, Epub ahead of print.
208. Aydemir O, Deveci A, Taskin OE, Taneli F, Esen-Danaci A: Serum brain-derived neurotrophic factor level in dysthymia: a comparative study with major depressive disorder. Progress in Neuropsychopharmacology & Biological Psychiatry, 2007, 31, 1023-1026.
209. Kim YK, Lee HP, Won SD, Park EY, Lee HY, Lee BH, et al.: Low plasma BDNF is associated with suicidal behavior in major depression. Progress in Neuropsychopharmacology & Biological Psychiatry, 2007, 31, 78-85.
210. Schüle C, Zill P, Baghai TC, Eser D, Zwanzger P, Wenig N, et al.: Brain-derived neurotrophic factor Val66Met polymorphism and dexamethasone/CRH test results in depressed patients. Psychoneuroendocrinology, 2006, 31, 1019-1025.
211. Frodl T, Schüle C, Schmitt G, Born C, Baghai T, Zill P, et al.: Association of the brain-derived neurotrophic factor Val66Met polymorphism with reduced hippocampal volumes in major depression. Archives of General Psychiatry, 2007, 64, 410-416.